Pricing Log in Create free account

Crescent Biopharma, Inc. (CBIO) vs Monopar Therapeutics Inc. (MNPR)

Crescent Biopharma, Inc. and Monopar Therapeutics Inc. are both Biotechnology companies. Crescent Biopharma, Inc. and Monopar Therapeutics Inc. are of similar size ($481.9M and $463.6M). Across the 8 metrics below, Monopar Therapeutics Inc. leads on 6 and Crescent Biopharma, Inc. on 2.

Valuation

Metric CBIO MNPR Biotechnology median
P/E n/m n/m 8.50
P/S 296.75 n/m 9.71
P/B 2.27 4.52 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 186.66 n/m 9.21
Earnings yield (56.76%) (3.13%) (33.15%)
Free cash flow yield (19.88%) (2.06%) (25.50%)

Profitability

Metric CBIO MNPR Biotechnology median
Gross margin 19.72% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (112.14%) (19.50%) (56.36%)
Return on assets (97.08%) (18.90%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CBIO MNPR Biotechnology median
Revenue growth (TTM) (45.09%) — 6.02%
EPS growth (last fiscal year) 44.97% 54.99% 30.26%
Revenue growth, 5-year CAGR 257.77% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CBIO MNPR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.66 33.56 4.72
Net debt to EBITDA 1.40 8.06 0.96

Dividend

Metric CBIO MNPR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CBIO MNPR Biotechnology median
Market cap 463.56m 481.93m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack